Wednesday, July 8, 2026

Drug profile · INN

hydralazine hydrochloride

hydralazine hydrochloride (HYDRALAZINE HYDROCHLORIDE) is a unknown. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 2
Pipeline programs 0
News articles 0
Drug details — hydralazine hydrochloride
US status
approved
Class
Route
INJECTION
Patents
2
Programs
0
Data quality
0.89

Quick answer

hydralazine hydrochloride (HYDRALAZINE HYDROCHLORIDE) is a unknown. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

Key facts

INN hydralazine hydrochloride
Brand HYDRALAZINE HYDROCHLORIDE
Mechanism Unknown
Route INJECTION
Formulation CAPSULE

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved
  1. US 10213389

    Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9463166

    Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is hydralazine hydrochloride?

hydralazine hydrochloride (HYDRALAZINE HYDROCHLORIDE) is a unknown. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

What is the brand name for hydralazine hydrochloride?

HYDRALAZINE HYDROCHLORIDE is a marketed brand name for hydralazine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of hydralazine hydrochloride?

hydralazine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.